EU's Tainted-Sartan Ban; Praluent Price Cut; Metoprolol Shortage Relieved?
Recent developments of interest in cardiovascular medicine
European regulators decided to ban any sartan with any level of contamination with probable carcinogenic nitrosamines, but is allowing a 2-year grace period to change manufacturing processes before enforcement. (in-Pharma Technologist.com)